F
Federico Lavorini
Researcher at University of Florence
Publications - 162
Citations - 5182
Federico Lavorini is an academic researcher from University of Florence. The author has contributed to research in topics: Inhaler & Medicine. The author has an hindex of 33, co-authored 137 publications receiving 3953 citations. Previous affiliations of Federico Lavorini include UniFi.
Papers
More filters
human athletes performing heavy sea-level exercise Counterpoint: Pulmonary edema does not occur in
A. William Sheel,Donald C. McKenzie,Antonio L,Cinzia Castagnini,Silvia Pellegrini,Maria Rosa Metelli,Remo Bedini,Vincenzo Lionetti,Andrea Piarulli,Giosuè Catapano,Valter Lubrano,Mirko Passera,Alessandro Pingitore,Erika Garbella,Paolo Piaggi,Danilo Menicucci,F. Frassi,William T. Chen,Peter D. Wagner,Christopher Davis,G. Kim Prisk,Susan R. Hopkins,Vince Tedjasaputra,Tatsuya J. Arai,Rebecca J. Theilmann,Sridhar S. Kumar,Massimo Pistolesi,Gerald S. Zavorsky,Federico Lavorini,Joseph P. Rienzi,Paul T. Cutrufello +30 more
Journal ArticleDOI
Contemporary Challenges in the Management of Asthma and Chronic Obstructive Pulmonary Disease: Expert Perspectives on Optimising Outcomes Through Guidelines Implementation, Inhaler Selection, and Patient Engagement
Tuula Vasankari,Federico Lavorini,Christer Janson,Lauri Lehtimäki,Eric D. Bateman,D. Singh,Charlotte Suppli Ulrik,Ashley Woodcock,Alvar Agusti +8 more
TL;DR: In this paper , dry power inhalers (DPI) have been proposed as a means of delivering effective treatment that combines ease of use and widespread acceptance among patients, with the potential to reduce medically-related emissions of greenhouses gases compared with pMDI.
Book ChapterDOI
Emerging Drugs for Chronic Cough
TL;DR: This chapter reviews emerging antitussive drugs that may down-regulate cough reflex sensitivity and the first antagonist, Gefapixant, has been studied in several hundred patients with chronic cough with resolution in the majority.
Journal ArticleDOI
Relationship between hyponatremia at hospital admission and cardiopulmonary profile at follow-up in patients with SARS-CoV-2 (COVID-19) infection
Danilo Malandrino,Ana Berni,Benedetta Fibbi,B. Borellini,Davies Cozzi,Dario Norello,Francesco Fattirolli,Federico Lavorini,Iacopo Olivotto,Carlo Fumagalli,Chiara Zocchi,Luigi Tassetti,L. Gozzi,Niccolò Marchionni,Mario Maggi,Aneta V. Peri,Michele Spinicci,Lorenzo Zammarchi,Leonardo Gori,Guja Bernacchi,L. Ciambellotti,Iacopo Vellere,Matteo Vannini,Sara Montali,Francesco Tonarelli,Viola Camartini,Giada Turrin,Giuseppe Dario Testa,Simona Virciglio,Enrico Gardellini,Carolina Corsi,Sofia Espinoza Tofalos,Rossella Marcucci,Laura Rasero,Lorenzo Giovannoni,L. Livi,Maria Vittoria Silverii +36 more
TL;DR: In this paper , the authors collected 6-month follow-up data from 189 laboratory-confirmed SARS-CoV-2 (COVID-19) patients previously admitted to a University Hospital and found that hyponatremia at admission was associated with worse echocardiography parameters related to right ventricular function.
Journal ArticleDOI
A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD
Simon Wan Yau Ming,John Haughney,Dermot Ryan,Iain Small,Federico Lavorini,Alberto Papi,Dave Singh,David M.G. Halpin,John R. Hurst,Shishir Patel,Matthias Ochel,Janwillem W. H. Kocks,Victoria Carter,Antony Hardjojo,David Price +14 more
TL;DR: Starting ICS/LABA treatment of COPD with extrafine-formulation BDP/FF was noninferior in preventing moderate/severe exacerbations compared to FP/SAL and BUD/FF.